2026-09-24T11:40:27.000Z · 4 days ago Profusa announces progress towards Lumee oxygen platform CE mark
Sep 24, 2026, 7:30 AM EDT · 4 days ago Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
Aug 31, 2026, 8:50 AM EDT · 4 weeks ago Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Aug 20, 2026, 8:30 AM EDT · 5 weeks ago Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Jul 31, 2026, 5:15 PM EDT · 1 month ago Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
2026-07-27T10:11:29.000Z · 2 months ago Profusa to acquire diagnostics company, appoints Jack Stover CEO
Jul 27, 2026, 6:00 AM EDT · 2 months ago Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
Jun 24, 2026, 8:00 AM EDT · 3 months ago Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
Jun 12, 2026, 8:00 AM EDT · 3 months ago Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Jun 10, 2026, 8:00 AM EDT · 3 months ago Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
May 15, 2026, 7:30 AM EDT · 4 months ago Profusa Announces Listing Transfer to The Nasdaq Capital Market
May 5, 2026, 8:30 AM EDT · 4 months ago Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
2026-04-06T10:05:05.000Z · 5 months ago Profusa announces $30M letter of intent for PanOmics diagnostic platform
Apr 6, 2026, 6:00 AM EDT · 5 months ago Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Feb 27, 2026, 9:15 AM EST · 7 months ago Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
Feb 19, 2026, 8:30 AM EST · 7 months ago Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
Feb 13, 2026, 8:30 AM EST · 7 months ago Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Jan 29, 2026, 8:00 AM EST · 8 months ago Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
Jan 16, 2026, 7:30 AM EST · 8 months ago Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
Dec 31, 2025, 7:30 AM EST · 9 months ago Profusa Bolsters European Commercial Network with New French Distributor, MedSell
Dec 30, 2025, 7:30 AM EST · 9 months ago Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35
Dec 15, 2025, 7:30 AM EST · 9 months ago Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
Dec 11, 2025, 8:30 AM EST · 9 months ago Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
Nov 24, 2025, 8:15 AM EST · 10 months ago Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
Nov 19, 2025, 5:44 PM EST · 10 months ago Profusa Announces Third Quarter Business and Financial Highlights
Oct 30, 2025, 7:30 AM EDT · 11 months ago Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
Oct 28, 2025, 8:30 AM EDT · 11 months ago Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
Oct 22, 2025, 8:30 AM EDT · 11 months ago Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
Oct 7, 2025, 8:15 AM EDT · 11 months ago Profusa Invests Additional $1 Million in Digital Treasury Assets
Oct 1, 2025, 8:30 AM EDT · 12 months ago Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base
Sep 11, 2025, 8:30 AM EDT · 1 year ago Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Sep 4, 2025, 8:30 AM EDT · 1 year ago Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
Aug 27, 2025, 8:45 AM EDT · 1 year ago Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
Aug 19, 2025, 8:15 AM EDT · 1 year ago Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO
Aug 6, 2025, 8:15 AM EDT · 1 year ago Profusa, Inc. Provides Strategy Overview and Business Update for Investors
Jul 21, 2025, 8:00 AM EDT · 1 year ago Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy
Jul 11, 2025, 4:00 PM EDT · 1 year ago Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq